March 12, 2016 | New Orleans, Louisiana
SOT is pleased to provide registrants these conference materials. Download the materials to your computer, smartphone, or tablet. All online meeting information is intended for registered miRNA meeting attendees.
Sunday, March 13, 2016
Meeting attendees have the opportunity to attend the AM05: Discovery and Validation of miRNA Biomarkers Bridging Preclinical and Clinical Toxicity: Lessons Learned from Hepatotoxicity on Sunday morning.
If you have already registered for this CE Course, you will have received a ticket for the course with your SOT Annual Meeting Badge. If you would like to register for the course or need assistance, please go to the Annual Meeting On-Site Registration counter.
Vision and Background
Long-term strategies are needed to coordinate future activities across different consortia, with an understanding of the efforts needed to progress a miRNA biomarker from discovery toward routine use in nonclinical and/or clinical safety assessment. Particular attention must be focused on the guidelines established by regulatory agencies for assessing new biomarkers, which have evolved along with the scientific efforts in this area. This conference will bring together scientists from the various consortia along with colleagues in academia and industry who are working independently with the goal of coordinating efforts toward identification and validation of miRNA biomarkers of toxicologic pathology.
MicroRNAs (miRNAs) are small, regulatory RNAs that control gene expression posttranscriptionally, thus acting as epigenetic regulators within cells. Recent data demonstrate that some miRNAs are specific to or enriched in certain cell types and/or organs and that they are released upon cellular damage, supporting their potential as non-invasive biomarkers of injury. Ease of detection and high stability at room temperature in biofluids contribute to enthusiasm of miRNAs as non-invasive biomarkers. miRNA detection is relatively straightforward with low inputs of material by quantitative real-time-PCR, microarray, or next-generation sequencing.
Several consortia efforts have been established to discover and validate miRNA biomarkers that
- provide insight into injury mode of action;
- distinguish the specific injury location and affected cell type; and/or
- are more sensitive for detection than “gold standard” protein biomarkers.
Critically, several of these biomarkers, particularly for liver injury, have progressed to clinical validation. Communication of recent discovery efforts and discussion of miRNA biomarker research efforts between consortia partners and independent researchers is a critical step toward the streamlined utilization of promising biomarkers for nonclinical and clinical safety assessment.
Program: Saturday, March 12, 2016
|9:00 AM–10:00 AM||
|10:00 AM–1:00 PM||
Plenary Session I: MiRNAs as Biomarkers of Tissue Injury or Disease across Organ Systems
The ILSI/HESI miRNA Rat Atlas Project to Identify Tissue-Specific miRNA Expression
Discovery of Glomerular Versus Tubular Injury Specific Urinary miRNA Biomarkers in Rodents
MiRNA-206 As a Useful Biomarker of Skeletal Muscle Injury
Plasma miRNAs as Potential Early Biomarkers for Acute Cardiac Injury
MiRNAs Signatures of Prostate Cancer in Urinary Exosomes
|10:00 AM–1:00 PM||Lunch and Poster Session – Room 217
All meeting attendees are encouraged to attend the Poster Session and enjoy a free lunch. More than 20 posters on current miRNA research will be presented. Network with your colleagues and enjoy some New Orleans favorites!
|10:00 AM–1:00 PM||
Plenary Session II – Technical Considerations for Measurement and Analysis of Small Non-Coding RNA in Biofluids
Measurement Methodology and Experimental Considerations for miRNA Quantification
Extracellular Vesicle Enrichment of miRNA in Biofluids
Classes of Small Non-Coding RNA in Biofluids
Reference Samples for miRNA Measurements
Bioinformatics Challenges for Next Generation Sequencing Analysis of miRNA Expression